To explore the value of serum Cystatin C (Cys-C) level in predicting the prognosis of patients with hyperthyroid heart failure.

89 patients with hyperthyroid heart failure were divided into a normal Cys-C group (46 cases) with a serum Cystatin C level <1.8 mg/L and a high Cys-C group (43 cases) with a serum Cystatin C level ≥1.8 mg/L. The clinical baseline data were compared between the two groups at admission. All the patients were followed up 180 days after discharge; and the cardiac death, malignant arrhythmias, and rehospitalization for cardiac function aggravation were defined as the outcome of the study. The event-free survival rates of the two groups were compared. COX proportional risk model was used to analyze the risk factors of the endpoint events in the patients.

Compared with the normal Cys-C group, the high Cys-C group had higher levels of NT-proBNP and LVDd and lower levels of LVEF and NYHA functional grading, with statistical differences (all P<0.05). The 180 d event-free survival rate in the high Cys-C group was 62.1%, and that in the normal Cys-C group 84.5%. There was a statistical difference in the event-free survival rate between two groups by Log-rank test (P<0.05). COX regression analysis showed that serum Cystatin C (RR=2.786, 95%CI: 1.076-7.119) was an independent risk factor for the poor prognosis in the patients.

Serum Cystatin C has inseparable relationship with the disease severity and prognosis of hyperthyroid heart failure, and it can be used as an indicator to evaluate the prognosis of patients with hyperthyroidism heart failure.

Serum Cystatin C; Hyperthyroidism heart failure; Prognosis